National trends in the ambulatory treatment of hypertension in the United States, 1997-2012

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Zhou, Meijia ^a   Daubresse, Matthew ^a   Stafford, Randall S ^b   Alexander, G Caleb ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LISINOPRIL; METOPROLOL; NIFEDIPINE; QUINAPRIL; TRIAMTERENE; VERAPAMIL; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION;

ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG USE; DRUG UTILIZATION; HYPERTENSION; PRESCRIPTION; PREVALENCE; UNITED STATES; ADOLESCENT; ADULT; AMBULATORY CARE; DRUG COMBINATION; HUMAN; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; UNITED STATES; YOUNG ADULT;

EID: 84928911805     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119292     Document Type: Article

References (27)

1. Hoyert DL, Xu J. Deaths: Preliminary data for 2011. National Vital Statistics Reports. 2012;61:1-52. PMID: 24964584
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21; 129(3):e28-e292. doi: 10.1161/01.cir.0000441139.02102.80 PMID: 24352519
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944. doi: 10.1161/CIR.0b013e31820a55f5 PMID: 21262990
4. Gu Q, Burt VL, Dillion CF, Yoon S. Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults with Hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126:2105-2114. doi: 10.1161/CIRCULATIONAHA.112. 096156 PMID: 23091084
5. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113:213-21. PMID: 16391156
6. Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48:846-52. PMID: 16982967
7. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137-1143. PMID: 14597641
8. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018 PMID: 15723979
9. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997-1005. PMID: 17378372
10. Volpe M, Tocci G, Bianchini F, De Rosa M, Fedozzi E, Covezzoli A, et al. AIFA Drug Monitoring Program: Aliskiren Registry. Use of aliskiren in a 'real-life' model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens. 2012 Jan; 30(1):194-203. doi: 10. 1097/HJH.0b013e32834e1c66 PMID: 22157325
11. Verpooten GA, Aerts A, Coen N, Vancayzeele S, Hermans C, Bowles J, et al. Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). Int J Clin Pract. 2011 Jan; 65(1):54-63. doi: 10.1111/j.1742-1241.2010.02562.x PMID: 21155943
12. Tocci G1, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granatelli A, et al. DRIVE Investigators. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy. High Blood Press Cardiovasc Prev. 2012 Jun. 1; 19(2):73-83. doi: 10.2165/11632170-000000000-00000 PMID: 22867093
13. Parving HH, Brenner BM, McMurray JJ, De Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes (ALTITUDE). N Engl J Med. 2012;367:2204-13. doi: 10. 1056/NEJMoa1208799 PMID: 23121378
14. Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A. A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. In: Proceedings of the survey research methods section, American Statistical Association (2000). Alexandirect renin inhibitorsa (Virginia): American Statistical Association. Available: http://www.webcitation.org/6FkoiUdLy. (Accessed June 20, 2011).
15. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61. PMID: 12570945
16. Higashi AS, Zhu S, Stafford RS, Alexander GC. National trends in outpatient asthma treatment, 1997-2009. Journal of General Internal Medicine. 2011;26:1465-70. doi: 10.1007/s11606-011-1796-4 PMID: 21769507
17. Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gottdiener JS, Burke GL, et al. Cardiovascular Health Study. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med. 2002 Nov. 11; 162(20):2325-32. PMID: 12418946
18. Chobanian AV, Bakris GL, Black HR, et al. the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. PMID: 14656957
19. Grimm PH, Flack JM. Alpha 1 Adrenreceptor Antagonists. J Clin Hypertens (Greenwich). 2011;13(9):654-657. doi: 10.1111/j.1751-7176.2011.00510.x PMID: 21896145
20. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013;311(5):507-520.
21. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PAC, et al. Why Don't Physicians Follow Clinical Practice Guidelines. JAMA. 1999;282:1458-1465. PMID: 10535437
22. Sosner P, Fiquet B, Quere S, Francillon A, Herpin D. How are physicians prescribing the direct renin inhibitor aliskiren in the management of essential hypertension? A French observational study. Journal of Hypertension. 2013;31:1491-1496. doi: 10.1097/HJH.0b013e328360f716 PMID: 24006041
23. Chauhan D, Mason A. Factors affecting the uptake of new medicines in secondary care-a literature review. J Clin Pharm Ther. 2008;33:339-48. doi: 10.1111/j.1365-2710.2008.00925.x PMID: 18613851
24. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure. Clin Ther. 2007;29:972-84. PMID: 17697916
25. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-62. PMID: 11827559
26. Rabbani A, Alexander GC. Out-of-pocket and total costs of fixed dose combination antihypertensives and their components. American Journal of Hypertension. 2008;21:509-13. doi: 10.1038/ajh.2008.31 PMID: 18437141
27. Gupta H, Kumar S, Roy SK, Gaud. Patent protected strategies. J Pharma Bioallied Sci. 2010;2:2-7.